<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02206867</url>
  </required_header>
  <id_info>
    <org_study_id>LG-ALCL001</org_study_id>
    <nct_id>NCT02206867</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Safety Study of LBAL in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group Clinical Study to Compare Pharmacokinetics, Safety and Tolerability of LBAL 40 mg With Humira® 40 mg After a Single Subcutaneous Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <brief_summary>
    <textblock>
      To compare PK, safety and tolerability of LBAL developed by LG Life Sciences Ltd. With those
      of Humira®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in serum over the time interval from 0 extrapolated to infinity</measure>
    <time_frame>0 to 65 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in serum</measure>
    <time_frame>0 to 65 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>LBAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Developed by LG Life Sciences</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abbvie</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LBAL</intervention_name>
    <description>Anti-inflammatory agents</description>
    <arm_group_label>LBAL</arm_group_label>
    <other_name>Adalimumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humira</intervention_name>
    <description>Anti-inflammatory agents</description>
    <arm_group_label>Humira®</arm_group_label>
    <other_name>Adalimumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 20-45 years old healthy males

          2. Body mass index 19.0 ~ 28.0 kg/m2

        Exclusion Criteria:

          1. Diagnosis of current or latent tuberculosis (TB); history of severe active chronic or
             local infection including TB

          2. Severe infection (e.g. sepsis) requiring admission or antibiotics treatment within
             four weeks prior to administration

          3. Clinically relevant previous or concomitant disease including hepatic, renal,
             neurological, respiratory, gastrointestinal, endocrine, hematologic, oncologic,
             cardiovascular, urinary, musculoskeletal or psychiatric, autoimmune disease/disorders

          4. Chronic or relevant acute infections. A negative result for human immunodeficiency
             virus (HIV), Hepatitis B (Hep B), and hepatitis C (Hep C) is required for
             participation (i.e. HIV Ab, HBsAg, HBcAb, HCV Ab)

          5. Fever greater than 38.3℃ within a week prior to administration of study drug

          6. Previous or current drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, M.D., Ph.D., M.B.A</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dep. of Clnical Pharmacology, Seoul National University College of Medicine and Hospital</affiliation>
  </overall_official>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2014</study_first_submitted>
  <study_first_submitted_qc>July 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2014</study_first_posted>
  <last_update_submitted>June 12, 2015</last_update_submitted>
  <last_update_submitted_qc>June 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

